EVP of R&D
OGT, United Kingdom
Dr. Graham Speight (PhD), Executive Vice President of R&D at Oxford Gene Technology (OGT) - A Sysmex Group Company
Graham joined OGT in 2007 following working in the pharmaceutical industry and for the Australian Cancer Research Foundation. As the Executive Vice President of R&D he now has overarching responsibility for the design, development and manufacture of all of OGT's FISH, microarray and NGS products.
His wealth of experience includes neuropsychiatry and cancer research, managing the identification and validation of a set of methylation and miRNA markers for the diagnosis and prognosis of cancer.
Over the last few years Graham has been successful in managing the early stage research through to delivery of novel RUO next generation sequencing (NGS) oncology and inherited disease products to global markets for OGT’s SureSeq™ brand. Under his direction, OGT has developed and launched a range of research panels for haematological and solid tumours and the team are currently developing a pipeline of follow-on NGS products.
More recently, alongside Sysmex’s global partners, Graham managed the successful development of a new IVD (PMDA) genetic testing system for IRD (Inherited Retinal Dystrophy). The software and panel contain 82 genes implicated in IRD, and has recently been cleared by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for Pre-Market Approval. This is a significant milestone for OGT, laying the foundation for future projects in the IVD space in which Graham has been a key driver.